SAN DIEGO--(BUSINESS WIRE)--Sequenom, Inc. (NASDAQ: SQNM) today announced the launch of an independent, prospective, multi-center observational study to document the performance of Sequenom’s SEQureDx™ Trisomy 21 technology for Down syndrome based upon Sequenom’s SEQureDx Technology. The study, RNA-based Noninvasive Aneuploidy (RNA), will be directed by Jacob Canick, Ph.D., Professor of Pathology and Laboratory Medicine, Brown University Medical School, and Glenn Palomaki, Associate Director, Division of Medical Screening, Women & Infants Hospital at Alpert Medical School of Brown University in Providence, Rhode Island.
